ArticleBioconjugate chemistry2026
MT1-MMP-Targeted Photoimmunotherapy via an IR700-Conjugated Bicyclic Peptide.
Article in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photoimmunotherapy (PIT) combines a photoabsorber conjugate with near-infrared light to trigger highly selective cancer cell destruction; however, current antibody-based agents remain expensive and exhibit slow systemic clearance. Here, a membrane-type 1 matrix metalloproteinase (MT1-MMP)-targeted bicyclic peptide was site-selectively conjugated with the photoabsorber IRDye700DX (bcMT1-IR700) to create a nonantibody scaffold for PIT. bcMT1-IR700 was chemically synthesized and confirmed by ESI-MS to possess a 1:1 peptide-to-dye ratio, and the absorption, excitation, and emission signatures of IR700 were maintained. In vitro, bcMT1-IR700 preferentially engaged MT1-MMP-overexpressing HT1080 cells, initially localized to the plasma membrane, and triggered rapid membrane blebbing and loss of viability upon 690 nm irradiation, whereas MT1-MMP-low A549 cells were largely unaffected except at the highest drug and light inputs. Following intravenous administration in HT1080 xenografts, bcMT1-IR700 accumulated rapidly within tumors and exhibited predominant renal clearance, and tumor-directed irradiation at 100 J/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.